Literature DB >> 22495144

Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons.

Jason L Dragoo1, Hillary J Braun, Jennah L Durham, Bethany A Ridley, Justin I Odegaard, Richard Luong, Steven P Arnoczky.   

Abstract

BACKGROUND: Numerous studies have shown platelet-rich plasma (PRP) preparations differ with respect to the inclusion of certain blood components, which may affect the host's cellular response. HYPOTHESIS: This study evaluated the inflammatory effect of Biomet GPS III leukocyte-rich PRP (LR-PRP) versus MTF Cascade leukocyte-poor PRP (LP-PRP) after intratendinous injection in an animal model. The authors anticipated that LR-PRP would incite a greater acute inflammatory response than LP-PRP. STUDY
DESIGN: Controlled laboratory study.
METHODS: A total of 17 skeletally mature New Zealand White rabbits were tested. In all cases, healthy patellar tendons were treated. In the control animals, one patellar tendon was injected with 2 mL autologous whole blood, and the other was injected with 2 mL sterile saline. Seven total tendons were injected with whole blood, and 7 tendons were injected with saline. In the experimental animals, one patellar tendon was injected with 2 mL LR-PRP, and the other was injected with 2 mL LP-PRP. Ten tendons were injected with LR-PRP, and 10 tendons were injected with LP-PRP. Animals were euthanized at 5 or 14 days after injection. Tendons were harvested and stained using hematoxylin and eosin and scored semi-quantitatively for total white blood cells (WBCs), mononuclear cells (macrophages and lymphocytes), polymorphonuclear cells (PMNs), vascularity, fiber structure, and fibrosis.
RESULTS: At 5 days after injection, tendons treated with LR-PRP had significantly greater overall tendon scores (6.3 ± 1.79 vs 1.8 ± 1.64, P = .012), as well as mean scores for fiber structure (1.4 ± 0.22 vs 0.50 ± 0.50, P = .012), denoting disrupted composition, total WBCs (1.1 ± 0.89 vs 0.10 ± 0.22, P = .014), mononuclear cells (macrophages and lymphocytes) (0.80 ± 0.45 vs 0.10 ± 0.22, P = .014), vascularity (1.7 ± 0.27 vs 0.80 ± 0.16, P = .008), and fibrosis (1.0 ± 0.35 vs 0.3 ± 0.45, P = .037) compared with tendons treated with LP-PRP. Otherwise, there were no significant differences in mononuclear cells (P = .590), PMN cells (P = 1.00), total WBCs (P = .811), vascularity (P = .650), or total tendon score (P = .596) in any of the treatment groups at 14 days.
CONCLUSION: Compared with leukocyte-poor Cascade PRP, leukocyte-rich GPS III PRP causes a significantly greater acute inflammatory response at 5 days after injection. There is no significant difference in the inflammatory response or cellularity regardless of the injection type at 14 days after intratendinous injection. CLINICAL RELEVANCE: Platelet-rich plasma injections are frequently prepared using commercial systems and are administered for clinical treatment of chronic tendinopathy. It is important to characterize the cellular responses elucidated by different injection preparations to further understand their effect on tissue healing and aid clinical decision making. Future investigations are necessary to apply these findings to the clinical setting.

Entities:  

Mesh:

Year:  2012        PMID: 22495144     DOI: 10.1177/0363546512442334

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  78 in total

1.  Experimental model for the study of the effects of platelet-rich plasma on the early phases of muscle healing.

Authors:  Paolo Borrione; Loredana Grasso; Elena Chierto; Stefano Geuna; Silvia Racca; Giuliana Abbadessa; Giulia Ronchi; Fabio Faiola; Alessia Di Gianfrancesco; Fabio Pigozzi
Journal:  Blood Transfus       Date:  2013-06-19       Impact factor: 3.443

2.  Reply to letter to the editor: Platelet-rich plasma injections for chronic plantar fasciitis.

Authors:  Nicolò Martinelli
Journal:  Int Orthop       Date:  2013-10-11       Impact factor: 3.075

Review 3.  Role of platelet rich plasma in rotator cuff tendinopathy- clinical application and review of literature.

Authors:  Akshay Phadke; Bijayendra Singh; Nik Bakti
Journal:  J Clin Orthop Trauma       Date:  2018-10-21

Review 4.  The use of platelet-rich plasma to augment conservative and surgical treatment of hip and pelvic disorders.

Authors:  Matthew J Kraeutler; Tigran Garabekyan; Omer Mei-Dan
Journal:  Muscles Ligaments Tendons J       Date:  2016-12-21

5.  Effect of light-emitting diodes, platelet-rich plasma, and their combination on the activity of sheep tenocytes.

Authors:  Jihad A M Alzyoud; Saleh A Al Najjar; Seham Talat; Basha'er Abu-Irmaileh; Yasser Bustanji; Abd Al-Rahman S Al-Shudiefat
Journal:  Lasers Med Sci       Date:  2018-10-13       Impact factor: 3.161

Review 6.  Platelet-Rich Plasma and the Knee-Applications in Orthopedic Surgery.

Authors:  Alexander Wasserman; Graeme Matthewson; Peter MacDonald
Journal:  Curr Rev Musculoskelet Med       Date:  2018-12

Review 7.  Platelet-Rich Plasma and Cartilage Repair.

Authors:  Mitchell I Kennedy; Kaitlyn Whitney; Thos Evans; Robert F LaPrade
Journal:  Curr Rev Musculoskelet Med       Date:  2018-12

8.  Platelet-rich plasma treatment improves outcomes for chronic proximal hamstring injuries in an athletic population.

Authors:  Ryan R Fader; Justin J Mitchell; Shaun Traub; Roger Nichols; Michelle Roper; Omer Mei Dan; Eric C McCarty
Journal:  Muscles Ligaments Tendons J       Date:  2015-02-05

9.  Combined intra-tendinous injection of Platelet Rich Plasma and bevacizumab accelerates and improves healing compared to Platelet Rich Plasma in tendinosis: comprehensive assessment on a rat model.

Authors:  Benjamin Dallaudiere; Olivier Zurlinden; Anne Perozziello; Lydia Deschamps; Ahmed Larbi; Liliane Louedec; Lionel Pesquer; Yohan Benayoun; Alain Silvestre; Jean Michel Serfaty
Journal:  Muscles Ligaments Tendons J       Date:  2014-11-17

Review 10.  Current Clinical Recommendations for Use of Platelet-Rich Plasma.

Authors:  Adrian D K Le; Lawrence Enweze; Malcolm R DeBaun; Jason L Dragoo
Journal:  Curr Rev Musculoskelet Med       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.